1. Lawson PA, Citron DM, Tyrrell KL, Finegold SM: Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe2016, 40:95–99. [PubMed] [Google Scholar]
2. Tickler IA, Obradovich AE, Goering RV, Fang FC, Tenover FC, Consortium HAI: Changes in molecular epidemiology and antimicrobial resistance profiles of Clostridioides (Clostridium) difficile strains in the United States between 2011 and 2017. Anaerobe2019. [PubMed] [Google Scholar]
3. Rupnik M, Wilcox MH, Microbiology G-DN: Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature Reviews Microbiology2009. [PubMed] [Google Scholar]
4. Rupnik M: Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS microbiology reviews2008, 32:541–555. [PubMed] [Google Scholar]
5. Lewis BB, Carter RA, Ling L, Leiner I, Taur Y, Kamboj M, Dubberke ER, Xavier J, Pamer EG: Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence. mBio2017, 8. [PMC free article] [PubMed] [Google Scholar]
6. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, et al.: Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome biology2009, 10. [PMC free article] [PubMed] [Google Scholar]
7. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al.: Burden of Clostridium difficile infection in the United States. N. Engl. J. Med2015, 372:825–34. [PMC free article] [PubMed] [Google Scholar]
8. Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, Nair H: Global burden of Clostridium difficile infections: a systematic review and meta-analysis. Journal of global health2019, 9:10407. [PMC free article] [PubMed] [Google Scholar]
9. Martin JS, Monaghan TM, Wilcox MH: Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nature reviews. Gastroenterology & hepatology2016, 13:206–216. [PubMed] [Google Scholar]
10. Moono P, Foster NF, Hampson DJ, Knight DR, Bloomfield LE, Riley TV: Clostridium difficile Infection in Production Animals and Avian Species: A Review. Foodborne pathogens and disease2016, 13:647–655. [PubMed] [Google Scholar]
11. Knetsch CW, Kumar N, Forster SC, Connor TR, Browne HP, Harmanus C, Sanders IM, Harris SR, Turner L, Morris T, et al.: Zoonotic Transfer of Clostridium difficile Harboring Antimicrobial Resistance between Farm Animals and Humans. Journal of clinical microbiology2018, 56. [PMC free article] [PubMed] [Google Scholar]
12. CDC: Clostridioides difficile. Edited by: Centers for Disease Control and Prevention; 2018. vol 2019.] [Google Scholar]
13. Rosa R, Donskey CJ, Munoz-Price LS: The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile. Current infectious disease reports2018, 20:27. [PubMed] [Google Scholar]
14. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP: Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. Journal of clinical microbiology2013, 51:2884–2892. [PMC free article] [PubMed] [Google Scholar]
15. Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Z Li J, Young VB: Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nature communications2014, 5:3114. [PMC free article] [PubMed] [Google Scholar]
16. Rojo D, Gosalbes MJJ, Ferrari R, Pérez-Cobas AE, Hernández E, Oltra R, Buesa J, Latorre A, Barbas C, Ferrer M, et al.: Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses. The ISME journal2015, 9:2206–2220. [PMC free article] [PubMed] [Google Scholar]
17. Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR: Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome2016, 4:12. [PMC free article] [PubMed] [Google Scholar]
18. Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR: Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Alimentary pharmacology & therapeutics2016, 43:1142–1153. [PMC free article] [PubMed] [Google Scholar]
19. Antharam VC, McEwen DC, Garrett TJ, Dossey AT, Li EC, Kozlov AN, Mesbah Z, Wang GP: An Integrated Metabolomic and Microbiome Analysis Identified Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in Clostridium difficile Infection. PloS one2016, 11. [PMC free article] [PubMed] [Google Scholar]
20. Jenior ML, Leslie JL, Young VB, Schloss PD: Clostridium difficile Alters the Structure and Metabolism of Distinct Cecal Microbiomes during Initial Infection To Promote Sustained Colonization. mSphere2018, 3. [PMC free article] [PubMed] [Google Scholar]The authors elucidate the global changes in transcription and metabolism of gut microbiome in mice treated with several different antibiotics and who varied in their resolution of C. difficile infection. This study is one of the first to use paired metatranscriptomics and metabolomics during enteric infection and demonstrates how C. diffiicle modulates the metabolism of the gut microbiome for its own benefit.
21. Fletcher JR, Erwin S, Lanzas C, Theriot CM: Shifts in the Gut Metabolome and Clostridium difficile Transcriptome throughout Colonization and Infection in a Mouse Model. mSphere2018, 3. [PMC free article] [PubMed] [Google Scholar]
22. Peters BM, Jabra-Rizk MA, O’May GA, Costerton JW, Shirtliff ME: Polymicrobial interactions: impact on pathogenesis and human disease. Clinical microbiology reviews2012, 25:193–213. [PMC free article] [PubMed] [Google Scholar]
23. Shen A: A Gut Odyssey: The Impact of the Microbiota on Clostridium difficile Spore Formation and Germination. PLoS pathogens2015, 11. [PMC free article] [PubMed] [Google Scholar]
24. Francis MB, Allen CA, Shrestha R, Sorg JA: Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS pathogens2013, 9. [PMC free article] [PubMed] [Google Scholar]
25. Sorg JA, Sonenshein AL: Bile salts and glycine as cogerminants for Clostridium difficile spores. Journal of bacteriology2008, 190:2505–2512. [PMC free article] [PubMed] [Google Scholar]
26. Heeg D, Burns DA, Cartman ST, Minton NP: Spores of Clostridium difficile Clinical Isolates Display a Diverse Germination Response to Bile Salts. PLoS ONE2012, 7. [PMC free article] [PubMed] [Google Scholar]
27. Long SL, Gahan CGMGM, Joyce SA: Interactions between gut bacteria and bile in health and disease. Molecular aspects of medicine2017, 56:54–65. [PubMed] [Google Scholar]
28. Staley C, Weingarden AR, Khoruts A, Sadowsky MJ: Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Applied microbiology and biotechnology2017, 101:47–64. [PMC free article] [PubMed] [Google Scholar]
29. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al.: Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature2015, 517:205–208. [PMC free article] [PubMed] [Google Scholar]
30. Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, Schürch CM, McCoy KD, Kuehne SA, Minton NP, et al.: Functional Intestinal Bile Acid 7α-Dehydroxylation by Clostridium scindens Associated with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model. Frontiers in cellular and infection microbiology2016, 6:191. [PMC free article] [PubMed] [Google Scholar]
31. Yoon S, Yu J, McDowell A, Kim SH, You HJ, Ko G: Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile. Journal of microbiology (Seoul, Korea)2017, 55:892–899. [PubMed] [Google Scholar]
32. Thanissery R, Winston JA, Theriot CM: Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. Anaerobe2017, 45:86–100. [PMC free article] [PubMed] [Google Scholar]In this study, the authors surveyed a range of human and mouse microbially-derived secondary bile acids on their ability to impact various aspects of the C. diffiicle life cycle. Their results showed that C. difficile strains were variably impacted by the inhibitory effects of secondary bile acids, highlighting the nuances in susceptibility to C. difficile colonization observed in vivo.
33. Sorg JA, Sonenshein AL: Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. Journal of bacteriology2010, 192:4983–4990. [PMC free article] [PubMed] [Google Scholar]
34. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A: Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. American journal of physiology. Gastrointestinal and liver physiology2014, 306:9. [PMC free article] [PubMed] [Google Scholar]
35. Seekatz AM, Theriot CM, Rao K, Chang Y-MM, Freeman AE, Kao JY, Young VB: Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe2018, 53:64–73. [PMC free article] [PubMed] [Google Scholar]A longitudinal analysis of patients treated with FMT for recurrent CDI revealed consistent increases in short chain fatty acids and variable increases in secondary bile acids post-FMT. By modeling metabolite concentrations and presence of specific bacteria, Lachnospiraceae, Ruminococcaceae, and unclassified Clostridiales were found to be associated with these restored metabolites.
36. Mullish BH, McDonald JAKAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGMGM, et al.: Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut2019, 68:1791–1800. [PMC free article] [PubMed] [Google Scholar]By analyzing the microbiome and metabolome of patients with recurrent CDI before and after FMT, this study determined that successful treatment was associated with a rapid and sustained enrichment in bile salt hydrolase-producing bacteria. The sufficiency of bile salt hydrolases in resolving recurrent CDI was further demonstrated in a mouse model.
37. Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, Khoruts A, Sadowsky MJ: Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PloS one2016, 11. [PMC free article] [PubMed] [Google Scholar]
38. Chandrasekaran R, Lacy DB: The role of toxins in Clostridium difficile infection. FEMS microbiology reviews2017, 41:723–750. [PMC free article] [PubMed] [Google Scholar]
39. Hofmann AF: The continuing importance of bile acids in liver and intestinal disease. Archives of internal medicine1999, 159:2647–2658. [PubMed] [Google Scholar]
40. Hamilton JP, Xie G, Raufman J-PP, Hogan S, Griffin TL, Packard CA, Chatfield DA, Hagey LR, Steinbach JH, Hofmann AF: Human cecal bile acids: concentration and spectrum. American journal of physiology. Gastrointestinal and liver physiology2007, 293:63. [PubMed] [Google Scholar]
41. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury B, Weimer BC, Monack DM, et al.: Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature2013, 502:96–99. [PMC free article] [PubMed] [Google Scholar]
42. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL: Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell host & microbe2014, 16:770–777. [PMC free article] [PubMed] [Google Scholar]
43. Mallonee DH, White WB, of bacteriologyH PB: Cloning and sequencing of a bile acid-inducible operon from Eubacterium sp. strain VPI 12708. Journal of bacteriology1990. [PMC free article] [PubMed] [Google Scholar]
44. Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Tho*ringer CK, Vehreschild MJGTJGT, Jazmati N, Rupp J, et al.: BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. PloS one2018, 13. [PMC free article] [PubMed] [Google Scholar]
45. Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee I-KK, Yun B-SS, Matsuzaki K, Furukawa M, Min H-KK, Bajaj JS, et al.: Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids. Cell chemical biology2019, 26:27–340000. [PMC free article] [PubMed] [Google Scholar]
46. Pamer E, Buffie C, McKenney P: Methods and compositions for reducing Clostridium difficile infection. US Patent2019.
47. Amrane S, Bachar D, Lagier JC, Raoult D: Clostridium scindens Is Present in the Gut Microbiota during Clostridium difficile Infection: a Metagenomic and Culturomic Analysis. Journal of clinical microbiology2018, 56. [PMC free article] [PubMed] [Google Scholar] Retracted
48. Dubois T, Tremblay YDNDN, Hamiot A, Martin-Verstraete I, Deschamps J, Monot M, Briandet R, Dupuy B: A microbiota-generated bile salt induces biofilm formation in Clostridium difficile. NPJ biofilms and microbiomes2019, 5:14. [PMC free article] [PubMed] [Google Scholar]
49. Yun B, Oh S, Griffiths MW: Lactobacillus acidophilus modulates the virulence of Clostridium difficile. Journal of dairy science2014, 97:4745–4758. [PubMed] [Google Scholar]
50. Yong CC, Lim J, Kim BKK, Park DJJ, Oh S: Suppressive effect of Lactobacillus fermentum Lim2 on Clostridioides difficile 027 toxin production. Letters in applied microbiology2019, 68:386–393. [PubMed] [Google Scholar]
51. Monteiro CRAVRAV, do Carmo MS, Melo BO, Alves MS, Dos Santos CI, Monteiro SGG, Bomfim MRQRQ, Fernandes ES, Monteiro-Neto V: In Vitro Antimicrobial Activity and Probiotic Potential of Bifidobacterium and Lactobacillus against Species of Clostridium. Nutrients2019, 11. [PMC free article] [PubMed] [Google Scholar]
52. Quigley L, Coakley M, Alemayehu D, Rea MC, Casey PG, O’Sullivan Ó, Murphy E, Kiely B, Cotter PD, Hill C, et al.: Lactobacillus gasseri APC 678 Reduces Shedding of the Pathogen Clostridium difficile in a Murine Model. Frontiers in microbiology2019, 10:273. [PMC free article] [PubMed] [Google Scholar]
53. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, et al.: Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS pathogens2012, 8. [PMC free article] [PubMed] [Google Scholar]
54. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC: Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. The Cochrane database of systematic reviews2017, 12. [PMC free article] [PubMed] [Google Scholar]
55. Banerjee P, Merkel GJ, Bhunia AK: Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut pathogens2009, 1:8. [PMC free article] [PubMed] [Google Scholar]
56. Najarian A, Sharif S, Griffiths MW: Evaluation of protective effect of Lactobacillus acidophilus La-5 on toxicity and colonization of Clostridium difficile in human epithelial cells in vitro. Anaerobe2019, 55:142–151. [PubMed] [Google Scholar]
57. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG: Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infection and immunity2012, 80:62–73. [PMC free article] [PubMed] [Google Scholar]
58. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, Viale A, Socci ND, van den Brink MR, Kamboj M, et al.: Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. The Journal of clinical investigation2010, 120:4332–4341. [PMC free article] [PubMed] [Google Scholar]
59. Winter SE, Lopez CA, Bäumler AJ: The dynamics of gut-associated microbial communities during inflammation. EMBO reports2013, 14:319–327. [PMC free article] [PubMed] [Google Scholar]
60. Pérez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJJ, Latorre A: Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Frontiers in microbiology2014, 5:335. [PMC free article] [PubMed] [Google Scholar]
61. Darkoh C, Plants-Paris K, Bishoff D, DuPont HL: Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule. mSystems2019, 4. [PMC free article] [PubMed] [Google Scholar]
62. Elsden SR, Hilton MG, of microbiologyW JM: The end products of the metabolism of aromatic amino acids by Clostridia. Archives of microbiology1976. [PubMed] [Google Scholar]
63. Passmore IJ, Letertre MPMPM, Preston MD, Bianconi I, Harrison MA, Nasher F, Kaur H, Hong HA, Baines SD, Cutting SM, et al.: Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria. PLoS pathogens2018, 14. [PMC free article] [PubMed] [Google Scholar]Production of a unique bacteriostic compound was determined to give C. difficile a competitive advantage in vivo against other enteric bacteria, primarily Gram-negative organisms. Furthermore, production of para-cresol during CDI changes the intestinal metabolic milieu, implicating it as a compound with wide-reaching effects.
64. Jalili-Firoozinezhad S, Gazzaniga FS, Calamari EL, Camacho DM, Fadel CW, Bein A, Swenor B, Nestor B, Cronce MJ, Tovaglieri A, et al.: A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nature biomedical engineering2019, 3:520–531. [PMC free article] [PubMed] [Google Scholar]A microfluidic device with biophysical and biochemical properties of the mammalian intestine enables extended co-culture of epithelial cells and anaerobic prokaryotes. Importantly, the diversity and composition of the human gut microbiome is recapitulated in this tool.
